The labelled use names who was studied

Some approved peptide products have labelled uses that name a sex or an obstetric setting. That is a fact about the product and the people in the trials. It is not a category of peptides.

Strand does not sort the catalog into men’s peptides and women’s peptides. A labelled use names who was studied for a specific product. The sequence does not inherit that use, and a nearby research compound does not inherit it either.

What the label is naming

Approved status attaches to a finished product and a labelled use. The use is the one the trials measured. If the trials enrolled only one population, the label can say so. That sentence is about the object in hand. It is not a sorting rule for other peptides.

Bremelanotide is labelled for premenopausal women with HSDD

The catalog marks bremelanotide approved. The FDA-approved product is Vyleesi. The labelled use is acquired, generalized hypoactive sexual desire disorder in premenopausal women. The prescribing information states that the product is not indicated for HSDD in postmenopausal women or in men, and it is not indicated to enhance sexual performance.

RECONNECT was the human measurement behind that sentence. Kingsberg et al. reported two identical randomized phase 3 trials in premenopausal women with HSDD. The trials were women-only. That is why the label names that population. It is not evidence that melanocortin agonists are a women’s class, and it is not a finding about unregulated products that share a research name.

Oxytocin is labelled for obstetric uses

The catalog marks oxytocin approved and High for the labelled obstetric uses. The FDA-approved product Pitocin is indicated to initiate or improve uterine contractions when that is medically indicated, and to produce uterine contractions in the third stage of labor and control postpartum bleeding. The label is an obstetric document. It is not a social-cognition document.

The live record already draws that line. Central and psychiatric uses remain experimental. Intranasal and social-behavior literature is mixed. Those studies do not move the labelled use, and the labelled use does not make oxytocin a women’s peptide. It makes Pitocin an obstetric medicine.

A labelled use can also be silent on sex

Tesamorelin’s labelled use is reduction of excess abdominal fat in HIV-associated lipodystrophy. That sentence is not sex-specific. Falutz et al. in 2007 enrolled a trial population that was mostly men. Who sat in the room and what the label later named are still two facts.

How to read the sentence

• Read the labelled use as the use the trials measured, including who was enrolled.
• Read a sex-specific or obstetric limitation as a fact about that product, not a class.
• Do not move the labelled use onto a research compound that shares a name.
• Do not invent a men’s-peptide or women’s-peptide shelf from two labelled examples.

The label will not tell you what to take. It will tell you who was studied for that product.